Glucose News and Research

RSS

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Eli Lilly and Company and Boehringer Ingelheim today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

11 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

A simpler form of testing individuals with risk factors for diabetes could improve diabetes prevention efforts by substantially increasing the number of individuals who complete testing and learn whether or not they are likely to develop diabetes.

7 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

Critical tuning dial for controlling whole body energy

Researchers have found what appears to be a critical tuning dial for controlling whole body energy, according to a new report in the January issue of Cell Metabolism, a Cell Press publication. When energy levels within cells drop, it sets off a series of events designed to increase the amount of calorie-rich dietary fat that the body will absorb.

5 Jan 2011

Removal of ZIP proteins from hippocampus cell protects them from injury

Researchers in the Blue Bird Circle Developmental Neurogenetics Laboratory in the department of neurology at Baylor College of Medicine have discovered that zinc enters cells through specialized protein gates known as ZIP transporters, and removing these ZIP proteins from cells in the hippocampus significantly protects them from injury.

5 Jan 2011

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

Qualcomm Incorporated and Telcare Incorporated today announced plans to integrate Qualcomm's wireless Internet of Everything Module (IEM) into the Telcare 3GM™ blood glucose meter being developed by Telcare. Telcare 3GM, currently in prototype phase, is designed to transfer blood glucose readings to a patient's family members or physician with each test.

5 Jan 2011

Study reviews effects of supplements on mental energy

The Life Sciences Research Organization, Inc. (LSRO) has published a review article in the December 2010 issue of Nutrition Reviews entitled Do Specific Constituents and Supplements Affect Mental Energy? Review of the Evidence.

5 Jan 2011

Diet low in micronutrients can contribute to metabolic syndrome

Results of an epidemiological study conducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and the Corporacion Ecuatoriana de Biotecnologia showed that the metabolic syndrome, a condition that increases a person's risk of developing cardiovascular disease and type 2 diabetes, was prevalent in a low-income urban community in Ecuador and that a poor diet low in micronutrients appeared to contribute.

5 Jan 2011

TRPM2 in pancreatic beta-cells may control insulin secretion levels

The research group led by professor Makoto Tominaga and Dr. Kunitoshi Uchida, National institute for Physiological Sciences, found TRPM2 ion channel in pancreatic beta-cells is important for insulin secretion stimulated by glucose and gastrointestinal hormone secreted after food intake. Their finding was reported in Diabetes.

4 Jan 2011

Health and Safety Watch tracks over 500 food and product advisories and recalls in 2010

This year Health and Safety Watch tracked more than 500 advisories and recalls issued for food and products in Canada. The events included everything from the recent Quaker Canada cereal bar recall due to the possible presence of peanuts, to big ticket items such as GE dishwashers recalled due to possible fire hazards.

30 Dec 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

24 Dec 2010

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.

23 Dec 2010

FDA joins Abbott Diabetes Careto to recall 359 glucose test strips

The test strips being recalled may give falsely low blood glucose results. False results may lead patients to try to raise their blood glucose unnecessarily, or they may fail to treat elevated blood glucose because of a false, low reading. Both scenarios pose risks to a patient's health.

22 Dec 2010

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

22 Dec 2010

Glucose News and Research

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Positive topline results from ZGN-433 Phase 1b study in obesity patients

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

Critical tuning dial for controlling whole body energy

Removal of ZIP proteins from hippocampus cell protects them from injury

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

Study reviews effects of supplements on mental energy

Diet low in micronutrients can contribute to metabolic syndrome

TRPM2 in pancreatic beta-cells may control insulin secretion levels

Health and Safety Watch tracks over 500 food and product advisories and recalls in 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

FDA joins Abbott Diabetes Careto to recall 359 glucose test strips

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News